Mankind Pharma and Innovent Biologics Partner to Launch Groundbreaking PD-1 Immunotherapy in India

Duchenne Muscular Dystrophy: Diagnosis, Treatment, and Emerging Therapies

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Form ImageneBio

Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

Home
/
update
/
details

PathAI Unveils PathExplore™ IOP and IHC Explore™ Products Ahead of ASCO 2024

NextEdge Admin

30 May 2024

3 min 4 sec

PathAI, a prominent figure in AI-powered pathology, has launched two groundbreaking AI products, PathExplore™ Immuno-Oncology Profiling (IOP) and IHC Explore1™, to empower cancer drug developers and clinical researchers with unprecedented insights. These innovations provide unparalleled single-cell and spatial resolution of the tumor microenvironment from routine pathology samples, facilitating biomarker discovery and enhancing understanding of treatment response for the next generation of cancer therapeutics.

PathExplore IOP accelerates the characterization of immune phenotypes crucial for identifying tumors likely to respond to immunotherapy. By quantifying tumor infiltrating lymphocytes (TILs) and their spatial distribution using routine hematoxylin and eosin (H&E) samples, researchers can gain insights into immune inflamed, desert, or excluded characteristics, ultimately leading to improved patient survival. PathExplore IOP’s AI-powered approach offers highly accurate and efficient immune phenotype classification, enabling researchers to inform biomarker strategies for patient stratification and mechanisms of response and resistance.

On the other hand, IHC Explore™ addresses the need for spatial quantification of IHC biomarkers in single-cell resolution with broad target compatibility. This product streamlines the process of defining optimal scoring systems for novel IHC assays, which is crucial in early stage biomarker development. By providing standardized features that quantify IHC stain abundance within and around cells of the tumor microenvironment, IHC Explore enables drug developers to build biomarker scoring strategies and identify patients most responsive to treatment. PathAI’s partnership with Roche further facilitates the translation of AI insights and scoring strategies into companion diagnostic development.

These advancements mark a significant step forward in AI-powered pathology, offering researchers and clinicians the tools they need to make meaningful advancements in cancer research, treatment, and care. With their commitment to providing accurate biological insights and improving patient outcomes, PathAI continues to lead the way in precision pathology, supporting laboratories, research institutions, and the biopharma industry in their transition to digital workflows and accelerating drug development for complex diseases.